Sign in Get in touch
World risk · Trade, tariffs and sanctions · US trade & foreign policy

The US raises its drug tariff on EU medicines above 15%

The test Between 26 Oct 2026 and 25 Oct 2027, the total US duty on patented medicines from the EU rises above 15% for at least one day, by a change to the Section 232 rate or by any other duty added on top.

Not under way · Confidence: medium · Reviewed 25 Oct 2026 · Scores from 1 to 10

This page answers: What could happen, how it is scored, and who is exposed?

Using this page
  1. Read the two scores: Likelihood and Impact are kept apart.
  2. Check what is happening, each fact with its source.
  3. Use the calendar for the dates to watch.

Follow this riskSign in to follow; one weekly email if you ask for it.

Likelihood
4Elevated steady this month
Impact
5Elevated steady this month
Breadth5
Depth4
Duration6
Hard to substitute5
Canada pointNot added0

Impact is the average of the four parts, rounded, plus one point when Canada is directly hit on two or more channels, up to 10.

Two separate scales from 1 to 10. Strature never multiplies or merges them.

What changed

Dated, newest first

  1. IMF DataMapper: Irish real GDP 8% in 2025, -1% in 2026, 3.7% in 2027 [4]
  2. ECB euro reference rate 1.1193 US dollars on 23 Oct 2026 [10]
  3. EU 15% all-in rate applies from 29 Sep 2026 (31 Jul for Annex III firms); generics exempt until April 2027; after the Supreme Court ruling the trade court ordered the IEEPA duties removed; Section 122 surcharge expired 24 Jul 2026; Section 232 goods exempt from Section 301 duty [2]
  4. Irish exports to the US EUR 35.2bn in Jan-Aug 2026, down 58% from EUR 83.6bn; medical and pharmaceutical exports EUR 51.6bn vs EUR 99.6bn; August medical and pharma EUR 6.0bn, -6.7% [3]
  5. RSM chief economist Thomas Pugh: over half of corporate tax receipts come from 10 multinational firms [6]
  6. Canada imported C$4.93bn from Ireland in 2025, 43% medicines (HS 30) [9]
  7. White Paper: corporation tax EUR 34bn in 2026, EUR 39bn in 2027 [5]

Why it matters

Since 29 Sep 2026 patented medicines from the EU have paid a US duty of 15% in all, against a default of 100% for countries without a deal. The same proclamation lets Washington raise a partner's rate if it fails to keep its commitments. In Strature's view Ireland is the EU member most exposed: its medical and pharmaceutical exports were EUR 51.6bn in January-August 2026, and RSM's chief economist says over half its corporate tax comes from 10 multinationals.

Why Likelihood 4 Pushes: clause 3(f) and paragraph 13 of the proclamation allow a rise; the German case; the US push for onshoring and pricing deals. Brakes: the EU rate was set only seven months ago; Section 232 drugs are kept out of the Section 301 duty on EU goods.

Why Impact 5 Threshold case a rate a little above 15% on EU patented medicines.

The other facts on file (3)
  • Section 232 proclamation: 100% default on patented medicines; 15% for the EU, Japan, South Korea, Switzerland-Liechtenstein; 20% onshoring tier; 0% with MFN pricing deal until 20 Jan 2029; clause 3(f) allows a rate rise for failure to fulfil commitments; generics excluded at this time [1] (2 Apr 2026)
  • USTR Section 301 investigation of Germany's underpayment for innovative drugs initiated 18 Jun 2026 [7] (24 Jun 2026)
  • Commission: 2025 GDP +12.3% driven by pharma exports likely front-loaded ahead of US tariffs; 2026 -1.2%; tax concentration in pharma and ICT a major risk [8] (21 May 2026)

Where it sits

11. The US raises its drug tariff on EU medicines above 15%: Elevated impact · possible1 · Elevated impact · possibleOttawaMexico CityCANADAMEXICOUNITED STATESPACIFIC OCEANATLANTIC OCEANGULF OF MEXICO01000 kmat 40°NMap data: Natural Earth (public domain).
11. The US raises its drug tariff on EU medicines above 15%: Elevated impact · possibleWashingtonCANADAMEXICOUNITED STATESGULF OF MEXICO0500 kmat 40°NMap data: Natural Earth (public domain).

How it spreads

If

Between 26 Oct 2026 and 25 Oct 2027, the total US duty on patented medicines from the EU rises above 15% for at least one day, by a change to the Section 232 rate or by any other duty added on top.

Not under way

Channels 4 on the card

  1. CanadaNo Canadian loss sourced; Canada's C$4.93bn of imports from Ireland in 2025 [9] are not touched by a US duty.
  2. Irish public financesA higher duty would test the EUR 39bn corporation-tax forecast for 2027 [5]; RSM's chief economist says over half of corporate tax comes from 10 multinationals [6].
  3. Trade and outputMore pressure to move production to the US, which the 20% and 0% tiers already reward [1].
  4. The EU-US dealA rise would signal the 15% all-in rate [2] is no longer a ceiling.

Who is exposed

Countries
Ireland, European Union, Germany, United States

Three scenarios and their signposts

  1. S1

    The deal holds

    The 15% rate stays and more firms move to the 20% or 0% tiers through onshoring and pricing deals.

  2. S2

    A partial squeeze

    The EU rate stays but generics are tariffed after the April 2027 review.

  3. S3

    The ceiling breaks

    Washington finds the EU short of its commitments and raises the rate under clause 3(f), or the German drug-pricing case ends in a duty that reaches medicines.

The signposts of each scenario
PathSignpost
S1No Federal Register notice changing the EU rate by 2 Apr 2027
S2The Commerce report on generics
S3A US finding against the EU in any trade case

No probability is given for the three paths.

Dates to watch

Calendar

The dates to watch

A dot is a day, a bar a month or a year; a hollow mark is tentative. The line marks today.

  1. Nov 2026 CSO goods exports for September 2026, the first month with the duty for all firms (from 29 Sep; October is the first full month) [3] Tentative · Outside event
  2. Apr 2027 Commerce report on tariffs for generic drugs due [1] Declared · Outside event
  3. 20 Jan 2029 Zero rate for firms with pricing deals ends [1] Declared · Outside event

    Remind me

  4. 2 Apr 2030 The 20% onshoring rate rises to 100% [1] Declared · Outside event

    Remind me

Sign in, with alerts on, for an email 7 days and 1 day before.

SourceStrature world-risk card; the dates cite the sources below.
Exhibit R-3 · IRELAND · strature.net

The other side

The 15% rate is far below the 100% default [1], which leaves EU-made medicines cheaper to ship to the US than those of countries without a deal. Ireland's growth outlook rests on solid global demand for the medicines it makes, in the Commission's words [8].

Connected in Strature

Sources

10 sources, numbered as the text cites them

  1. Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States. The White House · 2 Apr 2026 · Official · confidence high · retrieved 25 Oct 2026
  2. US tariffs: US and EU tariff measures in force. French customs (DGDDI) · 20 Oct 2026 · Official · confidence high · retrieved 25 Oct 2026
  3. Goods Exports and Imports August 2026, key findings. Central Statistics Office · 16 Oct 2026 · Official · confidence high · retrieved 25 Oct 2026
  4. Real GDP growth, Ireland, 2025-2027. IMF DataMapper (WEO) · edition not shown · International body · confidence medium · retrieved 25 Oct 2026
  5. Government forecast to record EUR 1.4bn Exchequer deficit, according to pre-budget White Paper. Irish Examiner · 2 Oct 2026 · News · confidence medium · retrieved 25 Oct 2026
  6. Budget 2027. RSM Ireland · 6 Oct 2026 · Industry · confidence medium · retrieved 25 Oct 2026
  7. Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products (2026-12671). USTR, Federal Register · 24 Jun 2026 · Official · confidence high · retrieved 25 Oct 2026
  8. Economic forecast for Ireland (Spring 2026). European Commission · 21 May 2026 · International body · confidence high · retrieved 25 Oct 2026
  9. Ireland dossier, rows IRL-us-tariffs-canada-eur-1 and IRL-us-tariffs-canada-scope-2 (Statistics Canada CIMT open data, 2025). Strature library · 6 Oct 2026 · Official · confidence high · retrieved 25 Oct 2026
  10. Euro foreign exchange reference rates, US dollar. European Central Bank · 23 Oct 2026 · Official · confidence high · retrieved 26 Oct 2026

Reviewed 25 Oct 2026 · version 1 · last change: reviewed · All risks